FDA Investigator Kurt A Brorson, PhD
Kurt A Brorson, PhD has inspections in 3 countries as of 11 Oct 2023. Kurt A Brorson, PhD has collaborated with a combinined 2329 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
7
Last Inspection Date:
11 Oct 2023
Investigator Role:
FDA Investigation Participant
Redica ID:
Country:
United States of America,
Korea (Republic of),
Germany
Co-Investigator(s):
Anastasia I Offordile,
Anastasia M Shields,
Anh M Lac,
Anita Narula, PhD,
Anita R Michael,
Ann L Demarco,
Ann Marie Montemurro,
Ashar P Parikh,
Azza Talaat,
Barbara J Holladay,
Barbara Janine Breithaupt,
Bo Chi, PhD,
Brenda W Uratani, PhD,
Byungja E Marciante,
Chaltu N Wakijra,
Charles R Bonapace, PhD,
Chiang Syin, PhD,
Christian D Lynch (CDL),
Christine M Smith,
Christine Mwhitby Smith,
Christopher Downey, PhD,
Concepcion Cruz, Jr,
Craig D Zagata,
Cynthia A Harris, MD, RN,
Cynthia Jim, CSO,
Cynthia White,
Daniel R Azar,
Debra Bower,
Diane L Raccasi,
Doan T Nguyen, PharmD,
Donald C Obenhuber, PhD,
Douglas A Campbell,
Dr. Mark J Seaton, PhD,
Dr. Ralph M Bernstein, PhD,
Dr. Zhou Chen (nmi), MD PhD,
Eliezar Ramos,
Emest F Bizjak,
Erika V Butler,
Erin L Mcfiren,
Felix Maldonado,
Gayle S Lawson,
George Pyramides,
Haoheng Yan, PhD,
Jacek Cieslak, PhD,
Jacqueline Mdiaz Albertini,
James M Mason,
Joan A Loreng,
John D White,
Joseph L Despins, PhD,
Julianne C Mccullough,
Julie D Bringger,
Junho Pak,
Justin A Boyd,
Jyoti B Patel, PhD,
Kalavati Suvarna, PhD,
Kathleen R Jones, PhD,
Kenneth Nieves,
Kevin A Gonzalez,
Ko U Min,
Kristen D Evans,
Kristin M Abaonza,
Kristina J Donohue,
Kristina Mjoyce Pittman,
Lakisha M Williams,
Lynette P Salisbury,
Marcelo O Mangalindan, Jr,
Marea K Harmon,
Mariza M Jafary,
Mark Brunswick, PhD,
Mary E Storch,
Matthew B Casale,
Michael F Skelly, PhD,
Michael Shanks, MS,
Michele M Falchek,
Michelle Y Clark Stuart,
Mihaly S Ligmond,
Milos Dokmanovic, PhD,
Monica Commerford, PhD,
Morris Paul,
Mra Munizn,
Nebil A Oumer,
Norman K Starks,
Omotunde O Osunsanmi,
Patricia Fhughes Troost,
Peter Adams, PhD,
Philip J Snoy,
Prabhu P Raju,
Qing Joanna Zhou, PhD,
Rachel C Harrington,
Reyes Candau Chacon, PhD,
Richard Heath Coats,
Richard Ledwidge (nmi), PhD,
Richard W Berning,
Riley C Myers, PhD,
Robert L Hummel,
Robert W Jennings,
Rose M Ashley,
Russell J Glapion,
Stephanie L Shapley,
Stephanie Mangigian, MS/OSH, RN,
Steven P Donald,
Stuart W Russell,
Subramanian Muthukkumar, PhD,
Susan M Jackson,
Susant Hadman,
Thomas E Friel,
Thuy T Nguyen, LCDR,
Toyin B Oladimeji,
Veronica Fuentes, MS,
Virgilio F Pacio, CSO,
Viviana Matta,
Vlada Matusovsky,
Walter N Lange,
Wayne E Seifert,
Yangmin Ning,
Yanming An, PhD,
Zerita White,
Zhihao Qiu (Peter), PhD,
Zhong Li, PhD,
Zhongren Wu,
Ziyang Su, PhD
Kurt A Brorson, PhD's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| February, 2004 | FDA 483 Response | Janssen Biotech, Inc. - Form 483R, 2004-03-10 |
| August, 2012 | EIR | WuXi Advanced Therapies Inc. - EIR, 2012-08-24 |
| February, 2004 | FDA 483 | Janssen Biotech, Inc. - Form 483, 2004-02-11 |
| May, 2004 | EIR | Boehringer Ingelheim Pharma GmbH and Co. KG - EIR, 2004-05-28 |
| July, 2012 | FDA 483 | Bioreliance Corporation - Form 483, 2012-07-03 |
| March, 2015 | EIR | CELLTRION Inc - EIR, 2015-03-06 |
| May, 2004 | FDA 483 Response | Boehringer Ingelheim Pharma GmbH and Co. KG - Form 483R, 2004-10-22 |
| June, 2002 | EIR | Boehringer Ingelheim Pharma GmbH and Co. KG - EIR, 2002-06-20 |
| March, 2015 | FDA 483 | CELLTRION Inc - Form 483, 2015-03-06 |
| September, 2014 | FDA 483 | Janssen Biotech, Inc. - Form 483, 2014-09-24 |
| June, 2002 | FDA 483 Response | Boehringer Ingelheim Pharma GmbH and Co. KG - Form 483R, 2002-06-28 |
| February, 2004 | EIR | Janssen Biotech, Inc. - EIR, 2004-02-11 |
Experience Redica System's NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more